Dr. Fins is chief of the Division of Medical Ethics in the Departments of Public Health and Medicine and professor of medicine, professor of public health and professor of medicine in ... The award is part of the Excellence in Medicine Awards program and
Rigotti said. “We shouldn't be renormalizing something that looks like smoking [without knowing] the long-term public health impact.”. ... of ‘tobacco product.’ Further research is needed to assess the potential public health benefits and risks
Dec. 8. The first study included 843,208 patients from one health system; all were 50 years of age or older and had received two doses of the Pfizer-BioNTech vaccine ... Understanding the protective effect of the booster dose in younger age groups is key
address and eliminate those disparities with contributions from professionals with expertise in basic science and pharmacology, clinical medicine, and public health,” the statement authors wrote. ... By successfully translating findings from across
result in notable public health benefit.” They called for interventions to increase awareness among patients and physicians and promote innovative collaborative care models. ... Regular monitoring of postfracture treatment rates, at both the health
With approximately 100 million adults in the U.S. suffering from chronic pain, the nonmedical use of prescription opioids has become a public health issue and prompted the FDA to establish
Health Association chose climate change as its theme for National Public Health Week 2008. ... Hurricanes, flooding and drought are all public health risks posed by a warming planet, experts said.
The deadline for abstract submissions is April 4. Abstract themes are guideline development and assessment; guideline implementation; personalized medicine guidelines; and guidelines, public health, and public policy.
Results were published online Aug. 8 and will appear in the September American Journal of Public Health.
Researchers at Johns Hopkins University Bloomberg School of Public Health in Baltimore reviewed published studies to uncover the potential benefits and harms of bisphosphonates, teriparatide, raloxifene, and denosumab compared with placebo,